BIOCYTOGEN-B (02315) rose more than 12% during intraday trading, accumulating a gain of approximately 30% over the past three days. At the time of writing, the stock was up 7.58% to HK$46, with a turnover of HK$53.8796 million.

On January 13, Biocytogen stated on an interactive platform that the company has completed the localized deployment of its AI-driven antibody drug development platform and achieved full synergy with its core business, the "Thousand Mice Ten Thousand Antibodies" initiative. Through this localized AI deployment, the company is building an AI agent for antibody drug development. As the deep integration of the "Thousand Mice Ten Thousand Antibodies" initiative and the AI system continues to advance, the company will provide global pharmaceutical companies with more efficient R&D tools and a richer library of antibody molecules, helping partner companies improve the R&D efficiency of preclinical PCC molecules, which will also propel the antibody discovery business into a new stage of development.

Furthermore, the company recently announced with Acepodia that the two parties have entered into an option and license agreement, aiming to conduct a systematic evaluation of bispecific antibody-drug conjugate (BsADC) projects through a structured assessment mechanism, thereby further accelerating the development process of bispecific antibody-dual drug conjugates (BsAD2C).